GSK Bets $2 Billion On Bellus Cough Drug To Soothe Pipeline Fears
By Natalie Grover and Aby Jose Koilparambil (Reuters) -GSK plans to buy Canada-based drug developer Bellus Health Inc in an all-cash deal for $2 billion as the British drugmaker expands its bet on respiratory therapies. The move to replenish its pipeline comes as GSK investors fret about whether there is enough in the medicine cabinet…
